by The global neurological biomarkers market size reached USD 9.14 billion by 2024 and is anticipated to cross around USD 30.77 billion by 2034 with a CAGR of 12.90% from 2024 and 2034.
Key Takeaways
- North America dominated the neurological biomarkers market with the largest market share of 40% in 2023.
- Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033.
- By type, the proteomic biomarkers segment dominated the market in 2023.
- By type, the other segments are anticipated to grow significantly during the forecast period.
- By application, the Alzheimer’s disease segment dominated the market in 2023.
- By application, the Parkinson’s disease segment is expected to grow substantially during the forecast period.
- By end-use, the research organizations & others segment dominated the neurological biomarkers market in 2023.
- By end-use, the hospital & hospital laboratories segment is estimated to be the fastest-growing during the forecast period.
Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/5109
Market Overview
The Neurological Biomarkers Market focuses on biological indicators that can identify neurological disorders, track disease progression, and assess responses to therapeutic interventions. These biomarkers, found in bodily fluids such as blood, cerebrospinal fluid, and saliva, are critical in diagnosing and monitoring neurological conditions, including Alzheimer’s, Parkinson’s, multiple sclerosis, and traumatic brain injuries. The demand for neurological biomarkers is driven by the growing prevalence of neurological disorders and the need for early detection and personalized medicine.
Growth Factors
The market is experiencing rapid growth due to advancements in biomarker discovery and validation, increased funding for neuroscience research, and rising awareness of neurological disorders. Government initiatives and private investments have also accelerated the development of innovative diagnostic tools, fostering market expansion. The growing focus on personalized medicine and the demand for precision diagnostics further contribute to the market’s growth, as biomarkers play a key role in tailoring treatments to individual patients.
Market Scope
| Report Coverage | Details |
| Market Size by 2034 | USD 30.77 Billion |
| Market Size in 2024 | USD 9.14 Billion |
| Market Growth Rate from 2024 to 2034 | CAGR of 12.90% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2034 |
| Segments Covered | Type, Application, End-use, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Market Dynamics
Drivers
A key driver of the Neurological Biomarkers Market is the increasing prevalence of neurological disorders worldwide, particularly among aging populations. Advances in genomics and proteomics are enhancing biomarker identification, leading to more accurate diagnostics and treatment options. Additionally, the push for early diagnosis and intervention in neurological disorders is driving demand for reliable biomarkers, as these markers enable healthcare professionals to detect diseases at their onset, improving patient outcomes.
Opportunities
The market presents significant opportunities for growth, particularly in the areas of research and development for novel biomarkers and advanced diagnostic technologies. Collaborations between pharmaceutical companies and research institutions are paving the way for innovative solutions and new biomarker discoveries. Emerging markets, particularly in Asia and Latin America, offer untapped potential due to rising healthcare investments and an increasing focus on neurological health. Additionally, advancements in artificial intelligence (AI) and machine learning are opening up new avenues for biomarker analysis and predictive modeling.
Challenges
Despite the promising outlook, the Neurological Biomarkers Market faces challenges such as high costs associated with biomarker research and validation, regulatory hurdles, and limited reimbursement policies. The complexity of neurological disorders also presents a challenge in biomarker identification, as these diseases often have multifactorial causes, making it difficult to pinpoint specific biomarkers. Additionally, ethical concerns around patient data and privacy may impact the widespread adoption of biomarker technologies.
Region Insights
North America dominates the Neurological Biomarkers Market due to substantial investments in neurological research, a strong healthcare infrastructure, and an increasing prevalence of neurodegenerative diseases. Europe follows closely, with growing research initiatives and government support for neurological health. The Asia-Pacific region is expected to witness rapid growth, driven by increased healthcare spending, a growing patient population, and a rising awareness of neurological disorders. Latin America and the Middle East & Africa are also anticipated to experience steady growth as healthcare systems continue to evolve and improve their focus on neurological conditions.
Read Also: Automotive Differential Market Size to Cross USD 38.53 Billion by 2034
Recent Developments
- In April 2024, in New York, new research to identify biomarkers for cerebral amyloid angiopathy (CAA) and related CAA-related inflammation by comparing measures of BBB (blood-brain barrier) disruption and inflammation between 2 groups of patients was launched by Presbyterian and Weill Cornell Medicine neurologist, Samuel Bruce, MD.
- In May 2024, to develop a new TBI (traumatic brain injury) diagnostics, with an added focus on diagnosing mild TBI, Danaher announced they launched a collaboration with Johns Hopkins University. It helps to potentially initiate a correlation between a new biomarker panel and clinical outcomes.
Neurological Biomarkers Market Players
- Rules-Based Medicin
- Alseres Pharmaceuticals, Inc.
- Quanterix
- Banyan Biomarkers, Inc.
- DiaGenic ASA
- Johnson & Johnson Services, Inc.
- Bio-Rad Laboratories, Inc.
- Merck & Co., Inc
- Thermo Fischer Scientific, Inc.
- Abbott
- Olink Biosciences
- ACOBIOM
- Enrolmmun
- ADx NeuroSciences NV
- Qiagen
- PERKINELMER INC.
- F. Hoffman La-Roche Ltd.
- Shimadzu Corporation
- Neurobio
- Myriad RBM (Myriad Genetics, Inc.)
Segments Covered in the Report
By Type
- Genomic
- Proteomic
- Metabolomic
- Imaging
- Others
By Application
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorder
- Others
By End-use
- Hospital & Hospital Laboratories
- Independent clinical diagnostic centers
- Research Organizations & Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/5109
Contact Us:
Mr. Alex
Sales Manager
Call: + 1 804 441 9344
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.dailystatsnews.com/
Blog: https://www.dailytechbulletin.com/
